EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
Leading pharmaceutical giants Pfizer and AstraZeneca have unveiled significant investment plans for France, totaling almost $1 billion. These announcements were made in anticipation of the annual 'Choose France' business summit, signaling a robust vote of confidence in the French economy by two of the world's foremost healthcare companies.
Pfizer's Pledge to French R&D
MSN reported that Pfizer has committed to investing 500 million euros ($538.5 million) in France, focusing on enhancing its research and development (R&D) capabilities within the country. This move aims to solidify France's position as a key player in the global healthcare research landscape, significantly boosting the local economy and job market.
AstraZeneca's Dunkirk Investment
Similarly, AstraZeneca announced an investment of $388 million to develop its Dunkirk site. This financial infusion is expected to expand the company's manufacturing and production capacities in France, further establishing the country as a critical hub in AstraZeneca's international operations.
The 'Choose France' Initiative
CNBC noted that these announcements arrived just as President Emmanuel Macron was gearing up to inaugurate the 'Choose France' event on Monday. Aiming to attract major overseas businesses and investors, the initiative underscores France's ambition to strengthen its appeal as a global business and investment destination.
Earlier statements also highlighted Morgan Stanley's creation of 100 new jobs in Paris and commitments from other international firms, such as German aviation innovator Lilium.
France's Global Business Ambition
Under President Macron's leadership, France is keen to enhance its stature as a premier European business capital, competing against traditional heavyweights like New York and London. Despite Paris's 14th place ranking in the recent Z/Yen global financial centers survey, these substantial investments by Pfizer and AstraZeneca are poised to contribute significantly to France's ambition of climbing the ranks as a top destination for global finance and business.
Photo: Pfizer Newsroom
